The FDA Voted. Now What? The Complete Road Map to What Happens After the PCAC Peptide Decision
By RUOcodes.com Research Team
Published: · Updated: Sep 6, 2026
FDA PCAC July 2026 vote: what the regulatory roadmap looks like for compounding peptides through 2027 and what researchers need to know now.
For research and educational purposes only. Not medical advice. This post follows our July 23 coverage of Day 1 PCAC votes on BPC-157, TB-500, KPV, and MOTS-c and our July 24 coverage of Day 2 results on Semax, Epitalon, and Emideltide . The short version: six of seven peptides received favorable advisory recommendations. Now the harder question — what actually happens next, and when? TL;DR: What the PCAC Vote Did and Did Not Do Six of seven peptides were recommended for inclusion on the 503A Bulk Drug Substances List by the FDA’s Pharmacy Compounding Advisory Committee on July 23 and 24, 2026. The internet immediately declared victory. That was premature. An advisory committee recommendation is not a regulatory change. No peptide is newly legal for compounding as a result of those votes. What actually happened is that the regulatory process moved to its next formal stage: FDA independent review, a Notice of Proposed Rulemaking, a public comment period, and a final rule. That process, under normal timelines, takes 12 to 24 months. The votes were genuinely good news. They were not the finish line. This post is the complete road map for what comes next. The Problem With How the PCAC Vote Is Being Covered In the 72 hours since the PCAC votes concluded on July 24, 2026, a pattern emerged in coverage that will cause real harm if it is not corrected. Outlets published headlines like “FDA Approves Peptides for Compounding” and “ BPC-157 Now Legal at Compounding Pharmacies.” Researchers posted asking where to get prescriptions filled. Telehealth platforms fielded inquiries about scheduling peptide therapy appointments. None of that is accurate. Not one peptide is newly authorized for compounding as a result of the July 2026 PCAC meeting. The meeting was a critically important step in a multi-step regulatory process. Understanding the full process — not just the step that just happened — is the difference between knowing what i…
← Back to Blog